Overview Java backend roles in 2026 demand strong fundamentals plus expertise in modern frameworks like Spring Boot and ...
NEW DELHI: A wave of affordable generic versions of Ozempic and Wegovy (semaglutide) has rapidly captured around 20% of the nearly Rs 1,600 crore weight-loss market within days of launch, following ...
Generic dapagliflozin is indicated for adults with type 2 diabetes and to reduce heart failure hospitalization risk in adults with T2D and established cardiovascular disease. The Food and Drug ...
LOWERING DRUG COSTS — Bipartisan lawmakers have revived efforts to require Medicare to cover generic drugs — and at least two biosimilars — with patients paying lower costs than for brand-name drugs, ...
The FDA approved the first generics of dapagliflozin (Farxiga) tablets for adults with type 2 diabetes, the agency announced on Tuesday. Generics of the SGLT2 inhibitor are indicated for glycemic ...
John Wilkerson is a Washington correspondent for STAT who writes about the politics of health care. He is also the author of the twice-weekly D.C. Diagnosis newsletter. Lizzy Lawrence leads STAT’s ...
March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. A woman removes a ...
https://www.thehindubusinessline.com/companies/generic-versions-of-novo-nordisks-semaglutide-begin-to-flow-priced-50-80-lower-than-the-innovator/article70769849.ece ...
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...
Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results